FilingReader Intelligence
Huadong Medicine unit gets FDA nod, plans board overhaul
June 30, 2025 at 05:19 PM UTC•By FilingReader AI
Huadong Medicine [SZSE:000963] has announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received U.S. FDA approval for its investigational new drug (IND) application for injectable HDM2012, allowing Phase I clinical trials to proceed in the United States for advanced solid tumors. HDM2012, a first-in-class biologic, is a novel antibody-drug conjugate (ADC) targeting Mucin 17 (MUC-17).
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Announcement on Adjustment of the Repurchase Price of the 2022 Restricted Stock Incentive PlanJune 30, 2025 at 08:00 AM UTC
Announcement of Board of Directors ElectionJune 30, 2025 at 08:00 AM UTC
Announcement on the Proposed Repurchase and Cancellation of Part of the Restricted Stocks and Reduction of the Company's Registered CapitalJune 30, 2025 at 08:00 AM UTC
SZSE:000963•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Huadong Medicine publishes news
Free account required • Unsubscribe anytime